Warning: The NCBI web site requires JavaScript to function. more...
The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?
Broersen K, Rousseau F, Schymkowitz J.
Alzheimers Res Ther. 2010 Jul 14;2(4):12.
Related citations
Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity.
Varadarajan S, Yatin S, Aksenova M, Butterfield DA.
J Struct Biol. 2000 Jun;130(2-3):184-208. Review.
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.
Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM.
Nature. 2009 Feb 26;457(7233):1128-32.
Assessing the stability of Alzheimer's amyloid protofibrils using molecular dynamics.
Lemkul JA, Bevan DR.
J Phys Chem B. 2010 Feb 4;114(4):1652-60.
Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
Götz J, Schild A, Hoerndli F, Pennanen L.
Int J Dev Neurosci. 2004 Nov;22(7):453-65. Review.
[Involvement of beta-amyloid in the etiology of Alzheimer's disease].
Tomiyama T.
Brain Nerve. 2010 Jul;62(7):691-9. Review. Japanese.
Oligomeric Intermediates in Amyloid Formation: Structure Determination and Mechanisms of Toxicity.
Fändrich M.
J Mol Biol. 2012 Jan 12. [Epub ahead of print]
Vaccination as a therapeutic approach to Alzheimer's disease.
Wisniewski T, Boutajangout A.
Mt Sinai J Med. 2010 Jan-Feb;77(1):17-31. Review.
Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering.
Sandberg A, Luheshi LM, Söllvander S, Pereira de Barros T, Macao B, Knowles TP, Biverstål H, Lendel C, Ekholm-Petterson F, Dubnovitsky A, Lannfelt L, Dobson CM, Härd T.
Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15595-600. Epub 2010 Aug 16.
Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease.
Lublin AL, Gandy S.
Mt Sinai J Med. 2010 Jan-Feb;77(1):43-9. Review.
Amyloid beta-peptide aggregation. What does it result in and how can it be prevented?
Nerelius C, Johansson J, Sandegren A.
Front Biosci. 2009 Jan 1;14:1716-29.
Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.
Roy S, Rauk A.
Med Hypotheses. 2005;65(1):123-37.
New developments in mild cognitive impairment and Alzheimer's disease.
Schott JM, Kennedy J, Fox NC.
Curr Opin Neurol. 2006 Dec;19(6):552-8. Review.
Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.
Solomon B.
Rejuvenation Res. 2008 Apr;11(2):349-57. Review.
Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death.
Resende R, Ferreiro E, Pereira C, Resende de Oliveira C.
Neuroscience. 2008 Aug 26;155(3):725-37. Epub 2008 Jun 19.
Vaccination for the prevention and treatment of Alzheimer's disease.
Solomon B, Frenkel D.
Drugs Today (Barc). 2000 Sep;36(9):655-63.
Mitochondria in aging and Alzheimer's disease.
Crouch PJ, Cimdins K, Duce JA, Bush AI, Trounce IA.
Rejuvenation Res. 2007 Sep;10(3):349-57. Review.
Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide.
Smith DP, Ciccotosto GD, Tew DJ, Fodero-Tavoletti MT, Johanssen T, Masters CL, Barnham KJ, Cappai R.
Biochemistry. 2007 Mar 13;46(10):2881-91. Epub 2007 Feb 13.
Inhibiting the conversion of soluble amyloid-beta peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer's disease therapy.
Soto C, Saborio GP, Permanne B.
Acta Neurol Scand Suppl. 2000;176:90-5.
Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra.
Barrow CJ, Yasuda A, Kenny PT, Zagorski MG.
J Mol Biol. 1992 Jun 20;225(4):1075-93.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on